Abstract
Abstract:Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disorder with a mortality rate of up to 90% if left untreated, and is characterized by microvascular thrombi, mainly in small arteries and capillaries, thrombocytopenia, hemolysis, and neurological abnormalities. Malignant hypertension (HTN) is a clinical syndrome characterized by severe hypertension associated with end-organ damage; including encephalopathy, renal dysfunction, and retinal hemorrhage due to platelet aggregation in the microcirculation leading to thrombotic microangiopathy (TMA). These are similar to TTP. Malignant hypertension can cause endothelial injury and fibrinoid necrosis in the vessel wall which results in its clinical manifestations. Therefore, it is difficult to differentiate malignant hypertension from TTP. However, it is critical to differentiate these two entities, as early initiation of plasmapheresis in TTP can be life saving. TTP is considered a masquerader as it can present with few clinical features and, if the index of suspicion is not very high, lead to mortality.
This content is limited to qualifying members.
If you have an existing account please login now to access this article or view purchase options.
Create a free account, then purchase this article to download or access it online for 24 hours.
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
References
References1. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991;325:393–397.RockGA]]ShumakKH]]BuskardNA&etal;Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.N Engl J Med1991325393-3972. Strandgaard S, Paulson OB. Cerebral blood flow and its pathophysiology in hypertension. Am J Hypertens 1989;2:486–492.StrandgaardS]]PaulsonOBCerebral blood flow and its pathophysiology in hypertension.Am J Hypertens19892486-4923. Gardiner DS, Lindop GB. Peripolar cells, granulated glomerular epithelial cells, and their relationship to the juxtaglomerular apparatus in malignant hypertension. J Pathol 1992;167:59–64.GardinerDS]]LindopGBPeripolar cells, granulated glomerular epithelial cells, and their relationship to the juxtaglomerular apparatus in malignant hypertension.J Pathol199216759-644. Möhring J, Möhring B, Näumann H-J, et al. Salt and water balance and renin activity in renal hypertension of rats. Am J Physiol 1975;228:1847–1855.MöhringJ]]MöhringB]]NäumannH-J&etal;Salt and water balance and renin activity in renal hypertension of rats.Am J Physiol19752281847-18555. McAllister RG Jr, Van Way CW III, Dayani K, et al. Malignant hypertension: effect of therapy on renin and aldosterone. Circ Res 1971;28(suppl 2):160–174.McAllisterRGJr]]Van WayCWIII]]DayaniK&etal;Malignant hypertension: effect of therapy on renin and aldosterone.Circ Res197128160-1746. Montgomery HE, Kiernan LA, Whitworth CE, et al. Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27. J Hypertens 1998;16:635–643.MontgomeryHE]]KiernanLA]]WhitworthCE&etal;Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27.J Hypertens199816635-6437. Brain MC. Microangiopathic hemolytic anemia. N Engl J Med 1969;281:833–835.BrainMCMicroangiopathic hemolytic anemia.N Engl J Med1969281833-8358. Sanerkin NG. Vascular lesions of malignant essential hypertension. J Pathol 1971;103:177–184.SanerkinNGVascular lesions of malignant essential hypertension.J Pathol1971103177-1849. Jones DB. Arterial and glomerular lesions associated with severe hypertension. Light and electron microscopic studies. Lab Invest 1974;31:303–313.JonesDBArterial and glomerular lesions associated with severe hypertension. Light and electron microscopic studies.Lab Invest197431303-31310. Vaughan CJ, Delanty N. Hypertensive emergencies. Lancet 2000;356:411–417.VaughanCJ]]DelantyNHypertensive emergencies.Lancet2000356411-41711. Kadiri S, Olutade BO. The clinical presentation of malignant hypertension in Nigerians. J Hum Hypertens 1991;5:339–343.KadiriS]]OlutadeBOThe clinical presentation of malignant hypertension in Nigerians.J Hum Hypertens19915339-34312. Cohen JA, Brecher ME, Bandarenko N. Cellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura. J Clin Apher 1998;13:16–19.CohenJA]]BrecherME]]BandarenkoNCellular source of serum lactate dehydrogenase elevation in patients with thrombotic thrombocytopenic purpura.J Clin Apher19981316-1913. Amorosi EL, Ultmann JE. Thrombocytopic purpura: report of 16 cases and review of the literature. Medicine (Baltimore) 1966;45:139–159.AmorosiEL]]UltmannJEThrombocytopic purpura: report of 16 cases and review of the literature.Medicine (Baltimore)196645139-15914. Moake JL, Turner NA, Stathopoulos NA, et al. Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation. J Clin Invest 1986;78:1456–1461.MoakeJL]]TurnerNA]]StathopoulosNA&etal;Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation.J Clin Invest1986781456-146115. Arya M, Anvari B, Romo GM, et al. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood 2002;99:3971–3977.AryaM]]AnvariB]]RomoGM&etal;Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers.Blood2002993971-397716. Sadler JE, Moake JL, Miyata T, et al. Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 2004:407–423.SadlerJE]]MoakeJL]]MiyataT&etal;Recent advances in thrombotic thrombocytopenic purpura.Hematology Am Soc Hematol Educ Program2004&NA;407-42317. Dong JF, Moake JL, Nolasco L, et al. ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 2002;100:4033–4039.DongJF]]MoakeJL]]NolascoL&etal;ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions.Blood20021004033-403918. Dong JF, Moake JL, Bernardo A, et al. ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor. J Biol Chem 2003;278:29633–29639.DongJF]]MoakeJL]]BernardoA&etal;ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor.J Biol Chem200327829633-2963919. Moake JL. von Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura. Semin Hematol 2004;41:4–14.MoakeJLvon Willebrand factor, ADAMTS-13, and thrombotic thrombocytopenic purpura.Semin Hematol2004414-1420. Zheng X, Majerus EM, Sadler JE. ADAMTS13 and TTP. Curr Opin Hematol 2002;9:389–394.ZhengX]]MajerusEM]]SadlerJEADAMTS13 and TTP.Curr Opin Hematol20029389-39421. Ruggeri ZM. Developing basic and clinical research on von Willebrand factor and von Willebrand disease. Thromb Haemost 2000;84:147–149.RuggeriZMDeveloping basic and clinical research on von Willebrand factor and von Willebrand disease.Thromb Haemost200084147-14922. Peyvandi F, Lavoretano S, Palla R, et al. Mechanisms of the interaction between two ADAMTS13 gene mutations leading to severe deficiency of enzymatic activity. Hum Mutat 2006;27:330–336.PeyvandiF]]LavoretanoS]]PallaR&etal;Mechanisms of the interaction between two ADAMTS13 gene mutations leading to severe deficiency of enzymatic activity.Hum Mutat200627330-33623. Schneppenheim R, Budde U, Oyen F, et al. von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP. Blood 2003;101:1845–1850.SchneppenheimR]]BuddeU]]OyenF&etal;von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP.Blood20031011845-185024. Peyvandi F, Lavoretano S, Palla R, et al. ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission. Haematologica 2008;93:232–239.PeyvandiF]]LavoretanoS]]PallaR&etal;ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission.Haematologica200893232-23925. Ono T, Mimuro J, Madoiwa S, et al. Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. Blood 2006;107:528–534.OnoT]]MimuroJ]]MadoiwaS&etal;Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure.Blood2006107528-53426. van den Born BJ, van der Hoeven NV, Groot E, et al. Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension. Hypertension 2008;51:862–866.van den BornBJ]]van der HoevenNV]]GrootE&etal;Association between thrombotic microangiopathy and reduced ADAMTS13 activity in malignant hypertension.Hypertension200851862-86627. George JN. How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000;96:1223–1229.GeorgeJNHow I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.Blood2000961223-122928. George JN. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med 2006;354:1927–1935.GeorgeJNClinical practice. Thrombotic thrombocytopenic purpura.N Engl J Med20063541927-193529. Allford SL, Hunt BJ, Rose P, et al. Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 2003;120:556–573.AllfordSL]]HuntBJ]]RoseP&etal;Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias.Br J Haematol2003120556-57330. Darabi K, Berg AH. Rituximab can be combined with daily plasma exchange to achieve effective B-cell depletion and clinical improvement in acute autoimmune TTP. Am J Clin Pathol 2006;125:592–597.DarabiK]]BergAHRituximab can be combined with daily plasma exchange to achieve effective B-cell depletion and clinical improvement in acute autoimmune TTP.Am J Clin Pathol2006125592-59731. Jasti S, Coyle T, Gentile T, et al. Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature. J Clin Apher 2008;23:151–156.JastiS]]CoyleT]]GentileT&etal;Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature.J Clin Apher200823151-156
